Substituted Heteroaryl Compounds for Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein kinase inhibitors lack efficacy and specificity in treating proliferative diseases, autoimmune diseases, inflammatory diseases, and cancer, with challenges in targeting Aurora, FLT3, and JAK kinases effectively while minimizing toxicity.
Innovation Solution
Development of novel substituted heteroaryl compounds that inhibit and modulate Aurora, FLT4, FLT3, and JAK kinases, offering improved pharmacological activities, selectivity, and reduced toxicity, with optimized pharmacokinetic properties and high bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current protein kinase inhibitors are used to treat proliferative diseases and cancer, then they can target Aurora, FLT3, and JAK kinases, but they lack efficacy and specificity while causing toxicity
Solution Approach 1:
The patent applies local quality by designing kinase inhibitors with specific molecular structures (substituted heteroaryl compounds) that are tailored to interact with particular kinase families (Aurora, FLT3, JAK). The compounds feature specific substitution patterns and heteroaryl cores that confer selectivity for target kinases, allowing differential binding affinities that improve efficacy while reducing off-target toxicity.
Solution Approach 2:
The patent employs parameter changes by systematically modifying chemical parameters of the inhibitor molecules, including substitution types (R1, R2, R3 groups), heteroaryl ring structures (A, T, W variables), and molecular configurations. These parameter modifications optimize the balance between binding affinity (efficacy) and selectivity (specificity), thereby reducing toxicity while maintaining therapeutic effectiveness.
2Reliability
If novel substituted heteroaryl compounds are developed to improve selectivity and reduce toxicity, then pharmacological activities are enhanced, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the kinase inhibitor into distinct functional modules: a core heteroaryl structure (A, T, W variables) and substituent groups (R1, R2, R3 variables). This modular design allows systematic optimization of selectivity and activity through targeted modification of specific segments, managing complexity through structured variability rather than random complexity.
Solution Approach 2:
The patent employs universality by designing a platform of substituted heteroaryl compounds where the core structure (Formula I variables) can target multiple kinase families (Aurora, FLT3, JAK). This multi-functional approach allows a single compound scaffold to address multiple disease indications and kinase targets, reducing overall complexity by using a universal platform rather than developing separate compounds for each target.
Data Source
AI summary
The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.